|
Antibiotics
|
Zone of inhibition (mm)
|
|---|
|
Gram Negative bacteria
|
Gram Positive bacteria
|
CLSI guideline
|
|---|
|
Escherichia coli
|
Pseudomonas aeruginosa
|
Staphylococcus epidermidis
|
Staphylococcus aureus
|
S
|
I
|
R
|
|---|
|
Cefepime
|
9
|
15
|
–
|
–
|
≥ 18
|
15–17
|
≤ 14
|
|
Ciprofloxacin
|
No zone
|
20
|
20
|
22
|
≥ 21
|
16–20
|
≤ 15
|
|
Imipenem
|
20
|
18
|
–
|
–
|
≥ 23
|
20–22
|
≤ 19
|
|
Cefoxitin
|
17
|
No zone
|
14
|
15
|
≥ 18
|
15–17
|
≤ 14
|
|
Ampicillin
|
No zone
|
No zone
|
18
|
No zone
|
≥ 17
|
14–16
|
≤ 13
|
|
Aztreonam
|
12
|
17
|
No zone
|
No zone
|
≥ 21
|
18–20
|
≤ 17
|
|
Tetracycline
|
8
|
No zone
|
No zone
|
18
|
≥ 15
|
12–14
|
≤ 11
|
|
Ceftazidime
|
10
|
14
|
–
|
–
|
≥ 21
|
18–20
|
≤ 17
|
|
Minocyclin
|
13
|
13
|
–
|
18
|
≥ 19
| |
≤ 14
|
|
Gentamycin
|
No zone
|
18
|
16
|
18
|
≥ 15
|
13–14
|
≤ 12
|
|
Co-trimoxazole
|
No zone
|
12
|
No zone
|
15
|
≥ 16
|
11–15
|
≤ 10
|
|
Colistin
|
9
|
12
|
No zone
|
No zone
|
≥ 11
| |
≤ 10
|
|
Clindamycin
|
No zone
|
No zone
|
No zone
|
No zone
|
≥ 21
|
15–20
|
≤ 14
|
|
Vancomycin
|
No zone
|
No zone
|
No zone
|
15
|
≥ 22
| |
≤ 21
|
|
Doxicyclin
|
12
|
12
|
–
|
18
|
≥ 16
| |
≤ 12
|
|
Erythromycin
|
7
|
No zone
|
No zone
|
20
|
≥ 23
|
14–22
|
≤ 13
|
|
Chloramphenicol
|
–
|
–
|
23
|
20
|
≥ 32
|
16
|
≤ 8
|
- Susceptible (S), intermediate (I) and resistant (R)
